Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $147.3 million.

  • Silence Therapeutics' Cash & Current Investments rose 52.01% to $122.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.4 million, marking a year-over-year increase of 52.01%. This contributed to the annual value of $147.3 million for FY2024, which is 39.31% up from last year.
  • Per Silence Therapeutics' latest filing, its Cash & Current Investments stood at $147.3 million for FY2024, which was up 39.31% from $105.8 million recorded in FY2023.
  • Silence Therapeutics' Cash & Current Investments' 5-year high stood at $147.3 million during FY2024, with a 5-year trough of $37.2 million in FY2020.
  • Over the past 3 years, Silence Therapeutics' median Cash & Current Investments value was $105.8 million (recorded in 2023), while the average stood at $107.0 million.
  • In the last 5 years, Silence Therapeutics' Cash & Current Investments surged by 172.24% in 2021 and then plummeted by 32.95% in 2022.
  • Over the past 5 years, Silence Therapeutics' Cash & Current Investments (MRY) stood at $37.2 million in 2020, then soared by 172.24% to $101.2 million in 2021, then tumbled by 32.95% to $67.8 million in 2022, then soared by 55.89% to $105.8 million in 2023, then skyrocketed by 39.31% to $147.3 million in 2024.
  • Its last three reported values are $147.3 million in FY2024, $105.8 million for FY2023, and $67.8 million during FY2022.